Mounjaro Online: Telehealth Routes

Yes. You can get Mounjaro online: a telehealth visit for the prescription, then a mail-order pharmacy. Hims & Hers charges $2,048 a month all in.

Telehealth from, all in: $2,048 a month
Prescription: RequiredFDA label (DailyMed)
Shortage: Resolved

Mounjaro key facts

How long the drug stays in your body

The half-life is about 5 days. By 5 d, half has left the body. Following five half-lives (25 d), about 3% remains.

Weight reduction in the main trial

In SURPASS-1, people with type 2 diabetes lost 7.8 kg over 40 weeks, compared with 1 kg on placebo.

Price across time

Listed and self-pay monthly prices are shown in US dollars. Each amount comes from the maker's price page.

Sources: FDA label (DailyMed), healthsystemtracker.org, pricinginfo.lilly.com.

Mounjaro: all legitimate ways to get it, ranked

Ways to get it, lowest cost first
Route	Who it is for	What you pay
Your doctor, with insurance and the savings card	Commercial insurance that covers it	For as little as $25, you can get up to a 3-month fill
Telehealth: Hims & Hers, Mounjaro	Online visit, medicine shipped	$2,048 a month all in

Prices checked November 2026. Each price links to its source page.

Sources: pricinginfo.lilly.com, mounjaro.lilly.com, GoodRx, FDA.

Who qualifies

Every GLP-1 requires a prescription in the US. A prescriber writes the prescription for an approved use listed on the label:

With diet and exercise, the drug lowers blood sugar in adults and children 10 and older with type 2 diabetes.
It lowers the chance of heart attack, stroke or death linked to the heart among high-risk adults with type 2 diabetes.

Needed: FDA label (DailyMed)

Telehealth options compared

Programs offering Mounjaro through telehealth
Program	Medicine option	Medicine price	Membership	All in
Hims & Hers	Mounjaro	$1,899 a month	$149 a month after first month	$2,048 a month

Each program's Prices come from its own pricing page. We make no money from any of them.

Source: hims.com.

Shortage status

Tirzepatide's Shortage has been resolved. On December 19, 2024, the FDA gave this confirmation.

First added to the FDA shortage list: December 15, 2022
Shortage resolved: December 19, 2024
State pharmacies had to stop making compounded copies on February 18, 2025
Outsourcing facilities had to stop on March 19, 2025

Source: FDA.

Scam signals

No prescription needed: the seller cannot be a pharmacy licensed in the US if it skips the prescription.
The FDA has not approved compounded drugs marketed as the brand, so they are not Ozempic, Wegovy, Mounjaro or Zepbound.
Misleading claims about a drug matching the brand led the FDA to send 30 warning letters to telehealth companies.
Harm reports: More than 730 adverse event reports linked to compounded tirzepatide are held by the FDA.
A monthly price that excludes the drug led the FTC to act against one program; see the NextMed review.

Sources: pricinginfo.lilly.com, mounjaro.lilly.com, GoodRx, FDA.

Find it in your state

Hims & Hers: some of the 50 states are not served
Noom Med: some of the 50 states are not served
NovoCare Pharmacy: its delivery network serves all 50 states, as well as DC, Puerto Rico

The route changes the most under Medicaid rules. Medicaid rules have the greatest effect on your route. For weight loss, 10 state Medicaid programs cover GLP-1s now. Select your state to view its drug list and prior authorization rules:

Sources: hims.com, noom.com, NovoCare.